Compare Gilead Sciences, Inc. (GILD) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Rent the Runway Inc — how do they compare? Gilead Sciences, Inc. trades at $148.6 (market cap $182.40B), while Rent the Runway Inc trades at $1.77 (market cap $61.75M). The key difference: Gilead Sciences, Inc. is far larger — about 2953.8× Rent the Runway Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Rent the Runway Inc for 56 Days on average.
| GILD | RENT | |
|---|---|---|
Market Cap | $182.40B | $61.75M |
Volume | 4,469,821 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $9.39 |
52-Week Low | $116.74 | $1.55 |
Typical Hold Time | 111 Days | 56 Days |
Enterprise Value | $205.46B | $228.75M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Rent the Runway (RENT) trades at $1.68, up 1.82% on the day, amid a bearish technical signal. The company reported revenue of $306.20M in 2025 with a net loss of $69.90M, though losses are narrowing year-over-year. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating mixed sentiment.
The outlook is cautious; while revenue growth and margin improvements are positive, negative shareholder equity and high debt levels pose significant risks. Analyst consensus is mixed with 42% buy ratings, but legal overhangs and profitability challenges temper near-term optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
